STOCK TITAN
  1. Home
  2. Sec-filings
  3. PALI
  4. [Form 3] Palisade Bio, Inc. Initial Statement of Beneficial Ownership

[Form 3] Palisade Bio, Inc. Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock PALI logo
Palisade Bio Inc

NASDAQ:PALI

PALI Rankings

#11098 Ranked by Market Cap
N/A Ranked by Dividends

PALI Latest News

Jul 9, 2025
Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors
May 27, 2025
Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis
May 6, 2025
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases
May 1, 2025
Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit
Apr 9, 2025
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

PALI Latest SEC Filings

Jul 9, 2025
[8-K] Palisade Bio, Inc. Reports Material Event

PALI Stock Data

3.90M
4.77M
0.8%
7.2%
4.99%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CARLSBAD